Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02698384 : Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Male or female aged 18 years or more, suffering from acromegaly

- Treatment naïve or treated subject (whatever the previous treatments except
Lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the
physician's opinion. Requiring a treatment with Somatostatin analog (SSA)

- Having performed a Magnetic Resonance Imaging (MRI) to evaluate the tumor size within
the previous 12 weeks (post-surgery MRI for operated subjects)

- In whom the physician has already decided to initiate a treatment with Lanreotide
120mg as a monotherapy

Exclusion Criteria:

- Subject previously/currently treated with Lanreotide 120mg

- History of radiotherapy for acromegaly

- Subject who requires a surgical intervention for relief of any sign or symptom
associated with tumor compression

- Concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists

- Active neoplastic disease
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02698384      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740